



PRESS RELEASE

MolMed: results of the independent study INGRID on the therapeutic potential of NGR-hTNF in brain lymphomas published by the prestigious journal Blood.

Milan (Italy), May 22nd 2019 – MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces that results of INGRID, independent pilot study on therapeutic potential of MolMed's therapeutic agent NGR-hTNF in brain lymphomas, have been published by *Blood*, the prestigious journal of the American Society of Hematology. The study was designed by Dr Andrés J. M. Ferreri, Head of the Lymphoma Unit of IRCCS San Raffaele Hospital in Milan, and principal investigator of the trial.

Brain lymphoma is a malignant tumor associated with poor survival mostly due by the limited capability of chemotherapy agents to achieve efficient concentration in brain tissue.

NGR-hTNF molecule has shown a synergic activity with standard chemotherapy for brain lymphomas: used in combination with R-CHOP, an immuno-chemotherapy employed in patients resistant to standard treatments, NGR-hTNF proved its ability to increase the permeability of blood vessels feeding the tumor mass, facilitating the permeabilization of the blood brain barrier, and allowing the combined therapy to enter the tumor.

Advanced brain diagnostic imaging techniques showed that 9 patients out of the 12 patients enrolled in INGRID study, whose first relevant results were presented at ASCO in June 2018, showed impressive and fast tumor regression, without significant toxicity/adverse event.

MolMed supported the study by providing *pro bono* the molecule to the San Raffaele research group.

The study was possible thanks to a grant from the Leukemia and Lymphoma Society of the USA.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which on March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with



PRESS RELEASE

Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

+39 02 21277.325

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it